EUVIMEDSkopri EUVIMED
Open access · CC BY-NC-ND 4.0

Forsythia velutina Nakai extract: A promising therapeutic option for atopic dermatitis through multiple cell type modulation

Yujin Kwon iD, Yoon Jin Kang iD, Jaeyoung Kwon iD, Su-Yeon Cho iD, Jiyoon Kim iD, Tam Thi Le iD, Hoseong Hwang iD, Barsha Deshar iD, Myungjun Kim iD, Ju Yeong Kim iD, Jae Hung Jung iD, Hyung-Sik Kim iD and 3 more

Allergy · 2024

DOI: 10.1111/all.15967 ↗

At a glance

Journal article in Allergy, 2024. Written by Yujin Kwon and 14 co-authors. Institution: Natural Product Research Center, Korea Institute of Science and Technology (KIST), Gangneung, Korea. Major MEDLINE topics: Dermatitis, Atopic, Plant Extracts, Disease Models, Animal, Forsythia. Cited 16 times so far (Crossref); 42 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Korea Institute of Science and Technology, National Research Foundation of Korea.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Atopic dermatitis (AD) is a complex condition characterized by impaired epithelial barriers and dysregulated immune cells. In this study, we demonstrated Forsythia velutina Nakai extract (FVE) simultaneously inhibits basophils, macrophages, keratinocytes, and T cells that are closely interrelated in AD development.

Methods

We analyzed the effect of FVE on nitric oxide and reactive oxygen species (ROS) production in macrophages, basophil degranulation, T cell activation, and tight junctions in damaged keratinocytes. Expression of cell‐type‐specific inflammatory mediators was analyzed, and the underlying signaling pathways for anti‐inflammatory effects of FVE were investigated. The anti‐inflammatory effects of FVE were validated using a DNCB‐induced mouse model of AD. Anti‐inflammatory activity of compounds isolated from FVE was validated in each immune cell type.

Results

FVE downregulated the expression of inflammatory mediators and ROS production in macrophages through TLR4 and NRF2 pathways modulation. It significantly reduced basophil degranulation and expression of type 2 (T2) and pro‐inflammatory cytokines by perturbing FcεRI signaling. Forsythia velutina Nakai extract also robustly inhibited the expression of T2 cytokines in activated T cells. Furthermore, FVE upregulated the expression of tight junction molecules in damaged keratinocytes and downregulated leukocyte attractants, as well as IL‐33, an inducer of T2 inflammation. In the AD mouse model, FVE showed superior improvement in inflammatory cell infiltration and skin structure integrity compared to dexamethasone. Dimatairesinol, a lignan dimer, was identified as the most potent anti‐inflammatory FVE compound.

Conclusion

Forsythia velutina Nakai extract and its constituent compounds demonstrate promising efficacy as a therapeutic option for prolonged AD treatment by independently inhibiting various cell types associated with AD and disrupting the deleterious link between them.

Subjects

MeSH terms (MEDLINE)

Dermatitis, AtopicPlant ExtractsDisease Models, AnimalForsythiaMacrophagesReactive Oxygen SpeciesAnimalsMiceAnti-Inflammatory AgentsHumansKeratinocytesCytokinesT-LymphocytesSignal TransductionBasophilsImmunomodulation

Author keywords

Forsythia velutina Nakaiatopic dermatitisepithelial barrierinflammationnatural product

Substances

Plant ExtractsReactive Oxygen SpeciesAnti-Inflammatory AgentsCytokines

Authors and institutions

  • Natural Product Research Center, Korea Institute of Science and Technology (KIST), Gangneung, Korea.
  • Division of Bio-Medical Science & Technology, University of Science and Technology (UST), Daejeon, Korea.
  • Department of Marine Life Sciences, College of Life Science, Gangneung-Wonju National University, Gangneung, Korea.
  • Natural Product Informatics Research Center, Korea Institute of Science and Technology (KIST), Gangneung, Korea.
  • Department of Pharmacology, Department of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Department of Biology, Gangneung-Wonju National University, Gangneung, Korea.

ORCID profiles: Yujin Kwon, Yoon Jin Kang, Jaeyoung Kwon, Su-Yeon Cho, Jiyoon Kim, Tam Thi Le, Hoseong Hwang, Barsha Deshar, Myungjun Kim, Ju Yeong Kim, Jae Hung Jung, Hyung-Sik Kim, Sang Hoon Jung, Hak Cheol Kwon, Won Kyu Kim

Funding

  • Korea Institute of Science and Technology
  • National Research Foundation of Korea

Cite

APA

Kwon, Y., Kang, Y. J., Kwon, J., Cho, S. Y., Kim, J., Le, T. T., Hwang, H., Deshar, B., Kim, M., Kim, J. Y., Jung, J. H., Kim, H. S., Jung, S. H., Kwon, H. C., & Kim, W. K. (2024). Forsythia velutina Nakai extract: A promising therapeutic option for atopic dermatitis through multiple cell type modulation. Allergy. https://doi.org/10.1111/all.15967

Vancouver

Kwon Y, Kang YJ, Kwon J, Cho SY, Kim J, Le TT, et al. Forsythia velutina Nakai extract: A promising therapeutic option for atopic dermatitis through multiple cell type modulation. Allergy. 2024. doi:10.1111/all.15967

BibTeX
@article{Kwon2024,
  author = {Kwon, Yujin and Kang, Yoon Jin and Kwon, Jaeyoung and Cho, Su-Yeon and Kim, Jiyoon and Le, Tam Thi and Hwang, Hoseong and Deshar, Barsha and Kim, Myungjun and Kim, Ju Yeong and Jung, Jae Hung and Kim, Hyung-Sik and Jung, Sang Hoon and Kwon, Hak Cheol and Kim, Won Kyu},
  title = {Forsythia velutina Nakai extract: A promising therapeutic option for atopic dermatitis through multiple cell type modulation},
  journal = {Allergy},
  year = {2024},
  doi = {10.1111/all.15967}
}
Start for free →